ReviewCNS neuroscience & therapeutics2019
Early compensatory responses against neuronal injury: A new therapeutic window of opportunity for Alzheimer's Disease?
Review in CNS neuroscience & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Task-based fMRI brain activation in mild cognitive impairment and Alzheimer's disease: an ALE meta-analysis.GeroScience · 2026Pooled it
- Translation of task-evoked negative BOLD response into aging and Alzheimer's disease: a systematic review of the current literature.Journal of translational medicine · 2025Pooled it
- Identification of functional near-infrared spectroscopy for older adults with mild cognitive impairment: a systematic review.Frontiers in aging neuroscience · 2025Pooled it
- Effects of accelerated intermittent theta-burst stimulation combined with cognitive training on brain function in amnestic mild cognitive impairment patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Trial
- Neuromodulation for restoring and amplifying brain function.Nature neuroscience · 2026Review
- Diagnostic Performance of the AlzoSure Predict Assay and Its Association With Alzheimer's Disease Biomarkers and Imaging Findings.Health science reports · 2026Article
- Five-year change in brain metabolism across the spectrum of cognitive impairment in older adults: a quantitative MRI study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Can Music Therapy Improve Cognition in Dementia as Measured with Magnetoencephalography: A Hypothesis Study.Biomedicines · 2026Article
- Low concentrations of amyloid-beta oligomers induce synaptogenesis characteristic for mild cognitive impairment and alter the de novo proteome.Translational psychiatry · 2026Article
- Dysregulated glucose metabolism in the visual cortex of human subjects with mild cognitive impairment and Alzheimer's disease.Frontiers in aging neuroscience · 2026Article
- Hypoxia reverses the early anti-inflammatory microglial response to the β-amyloid peptide: mitochondrial involvement and beneficial roles of melatonin and naringenin.Journal of translational medicine · 2025Article
- Sex-Associated Cerebellar and Hippocampal Volume Reduction in Alzheimer's Disease: Insights from the Clinical ADNI Cohort and STZ Animal Model.International journal of molecular sciences · 2025Article
- Temporal transcriptomic changes in the THY-Tau22 mouse model of tauopathy display cell type- and sex-specific differences.Acta neuropathologica communications · 2025Article
- Magnetic stirring with iron oxide nanospinners accretes neurotoxic AβMaterials today. Bio · 2024Article
- Increased between-network connectivity: A risk factor for tau elevation and disease progression.Neuroscience letters · 2024Article
- Association between plasma Netrin-1 levels and motor and nonmotor symptoms in Parkinson's disease.CNS neuroscience & therapeutics · 2024Article
- Upregulated ECM genes and increased synaptic activity in Parkinson's human DA neurons with PINK1/ PRKN mutations.NPJ Parkinson's disease · 2024Article
- Article
- Correlation of Presynaptic and Postsynaptic Proteins with Pathology in Alzheimer's Disease.International journal of molecular sciences · 2024Article
- Oxidative stress in Alzheimer's disease: current knowledge of signaling pathways and therapeutics.Molecular biology reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is characterized by extensive neurodegeneration and inflammation in selective brain areas, linked to severely disabling cognitive deficits. Before full manifestation, different stages appear with progressively increased brain pathology and cognitive impairment. This significantly extends the time lag between initial molecular triggers and appearance of detectable symptoms. Notably, a number of studies in the last decade have revealed that in the early stage of mild cognitive impairment, events that appear in contrast with neuronal distress may occur. These have been reproduced in vitro and in animal models and include increase in synaptic elements, increase in synaptic and metabolic activity, enhancement of neurotrophic milieu and changes in glial cell reactivity and inflammation. They have been interpreted as compensatory responses that could either delay disease progression or, in the long run, result detrimental. For this reason, these mechanisms define a new and previously undervalued window of opportunity for intervention. Their importance resides especially in their early appearance. Directing efforts to better characterize this stage, in order to identify new pharmacological targets, is an exciting new avenue to future advances in AD research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.